News

A grant from the “la Caixa” Foundation allows Albert Antolín to set up his research at IDIBELL

Yesterday the award ceremony of the “la Caixa” Foundation scholarships was held. Dr. Albert Antolín, principal investigator of IDIBELL and ICO, received a Junior Leader grant to develop new strategies based on Big Data and artificial intelligence for the design of drugs against cancer that prevent drug resistance.

Leer más about A grant from the “la Caixa” Foundation allows Albert Antolín to set up his research at IDIBELL

IDIBELL joins Brain Week with two scientific dissemination proposals

The play Abans que arribi l’alemany, about Alzheimer’s, and a flash talks session about Parkinson’s, bring neurodegenerative diseases closer to the public.

Leer más about IDIBELL joins Brain Week with two scientific dissemination proposals

Presentation of the new cell sorter of the flow cytometry platform

The Flow Cytometry Platform of the IDIBELL Scientific-Technical Services incorporated new high-performance equipment. It is the Beckman Coulter CytoFLEX SRT Benchtop Cell Separator. The arrival of this state-of-the-art equipment covers the need to renew the cell separation service and makes new and current technological improvements available to researchers. CytoFLEX SRT can meet the requirements for […]

Leer más about Presentation of the new cell sorter of the flow cytometry platform

Study describes the structural and functional effects of several mutations on the androgen receptor

The androgen receptor is the main target in the fight against prostate cancer. The study, published in the journal Science Advances, states that the analyzed mutations affect several functional regions of the union domain of the androgen receptor to testosterone.

Leer más about Study describes the structural and functional effects of several mutations on the androgen receptor

The DACMA Association donates 10,000 euros for breast cancer research

Yesterday, this association from Sant Joan Despí organized an event in which Dr. Sonia Pernas from IDIBELL and the ICO presented the current situation of breast cancer research.

Leer más about The DACMA Association donates 10,000 euros for breast cancer research

Smoking increases the risk of developing severe COVID by 30 to 50%

This is the main conclusion of a study published in the scientific journal ‘European Respiratory Review’ in which the head of the IDIBELL Tobacco Control research group and head of the Tobacco Control Unit of the Catalan Institute of Oncology, Esteve Fernández, has participated. The article analyzes the results in this field in the different reports presented to date.

Leer más about Smoking increases the risk of developing severe COVID by 30 to 50%

The Association Against Cancer in Barcelona finances four IDIBELL projects with almost 500,000 euros

The IDIBELL projects by Elisa Espinet, Juan José Rojas, Carolina M. Florian, and Victor Moreno have been selected. All of them presented this Monday in an act with a round table of the most outstanding grants and a dialogue between doctor and patient.

Leer más about The Association Against Cancer in Barcelona finances four IDIBELL projects with almost 500,000 euros

New study identifies an epigenetic signature associated to the rare genetic disorder GATA2 deficiency

The results show that patients with this disorder have abnormal genetic and epigenetic patterns, which could contribute to the development of diverse clinical manifestations, such as compromise the ability of blood cell production.

Leer más about New study identifies an epigenetic signature associated to the rare genetic disorder GATA2 deficiency

IDIBELL and CNIO researchers propose biomarkers to select patients with breast cancer who could benefit from treatment with Denosumab

“These results reactivate the option of clinical trials with Denosumab in breast cancer selected patients”, says Eva González-Suarez, CNIO and IDIBELL researcher and lead author.

Leer más about IDIBELL and CNIO researchers propose biomarkers to select patients with breast cancer who could benefit from treatment with Denosumab
Scroll to Top